Syndax Pharmaceuticals announces preliminary unaudited financial results for the fourth quarter and full year 2025, positioning for further growth.
The revenue performance of Revuforj and Niktimvo in 2025 reflects strong demand for Syndax's innovative cancer therapies.
Syndax's robust cash position at the end of 2025 sets a solid foundation for profitability and industry advancement.
Revuforj Performance
Revuforj achieved $44 million in net revenue for Q4 2025 and $125 million for the full year, exhibiting a notable 38% revenue increase in Q4 compared to the previous quarter.
Niktimvo Revenue
Niktimvo recorded $56 million in net revenue for Q4 2025 and $152 million for the full year; Syndax will disclose its share of the net profit at a later date.
Cash Position
Ending 2025 with around $394 million in cash, cash equivalents, and marketable securities, Syndax ensures sustainable funding to drive profitability and growth.
- The successful introduction of Revuforj and Niktimvo in 2025 marks a pivotal phase for Syndax, laying the groundwork for future expansion and innovation in 2026.
- Building on its current momentum and patient reach, Syndax aims to consolidate its foothold in the cancer therapy market and optimize the impact of its treatment offerings.
Syndax Pharmaceuticals' 2025 financial performance signifies strategic progress in delivering cutting-edge cancer treatments and underscores a commitment to profitability and expansion. Positioned for a promising year ahead, Syndax is poised for sustained success in the healthcare industry.